USPTO Examiner DEBERRY REGINA M - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18666190ANTI-CXCR2 ANTIBODIES AND USES THEREOFMay 2024September 2025Abandon1601NoNo
18624726DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATIONApril 2024July 2025Abandon1510NoNo
18444110ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATIONFebruary 2024September 2025Abandon1911NoNo
18401874Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJanuary 2024July 2025Abandon1801NoNo
18396187ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOFDecember 2023August 2025Allow2010NoNo
18538465ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOFDecember 2023May 2025Abandon1710NoNo
18509252BISPECIFIC ANTI-CCL2 ANTIBODIESNovember 2023April 2024Allow511YesNo
18481884ANTIBODIES AGAINST TIM3 AND USES THEREOFOctober 2023March 2025Abandon1810NoNo
18478374TREATMENT OF HIDRADENITIS SUPPURATIVASeptember 2023April 2025Abandon1810NoNo
18464025ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDESSeptember 2023February 2024Allow511NoNo
18335941BISPECIFIC ANTI-CCL2 ANTIBODIESJune 2023October 2025Allow2911NoNo
18312897ANTI-OPG ANTIBODIESMay 2023June 2025Allow2511NoNo
18126528METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSISMarch 2023October 2025Abandon3120NoNo
18156016METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASEJanuary 2023February 2025Abandon2511NoNo
18068506METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVESDecember 2022June 2025Abandon3011NoNo
18052180SINGLE-CHAIN TNF RECEPTOR 2 AGONIST FUSION PROTEINSNovember 2022March 2025Allow2820YesNo
17916337COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALINGSeptember 2022March 2026Allow4211NoNo
17906741PEPTIDE FOR PREVENTING OR TREATING HAIR LOSS, AND USE THEREOFSeptember 2022April 2025Allow3110NoNo
17929232Aqueous Antibody Formulation Stabilized by Antioxidants for Parenteral AdministrationSeptember 2022July 2025Allow3530NoNo
17823883PRODUCTION OF GLYCOPROTEINS USING MANGANESEAugust 2022March 2025Allow3020NoNo
17819200METHODS, REGIMENS, COMBINATIONS & ANTAGONISTSAugust 2022July 2025Abandon3511NoNo
17818927ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USESAugust 2022April 2025Abandon3211NoNo
17853218ANTI-CCL17 ANTIBODIESJune 2022May 2024Allow2221NoNo
17785243Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic DermatitisJune 2022March 2026Allow4511NoNo
17751433THYROID STIMULATING HORMONE COMPOSITIONSMay 2022October 2024Abandon2901NoNo
17737965METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODYMay 2022March 2025Allow3530NoNo
17718622ANTI-CXCR2 ANTIBODIES AND USES THEREOFApril 2022February 2024Allow2210NoNo
17700251RECOMBINANT HUMAN EPO-FC-FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVOMarch 2022April 2024Abandon2510NoNo
17761727DOSING FOR ANTI-TRYPTASE ANTIBODIESMarch 2022December 2025Abandon4510NoNo
17639096CR2 Binding Proteins and their use in Medical TherapyFebruary 2022January 2026Allow4711NoNo
17681219ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSFebruary 2022October 2023Allow2011NoNo
17629730METHODS OF MEASURING CELL-MEDIATED KILLING BY EFFECTORSJanuary 2022January 2026Abandon4711NoNo
17579683CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOFJanuary 2022March 2025Abandon3812NoNo
17579581METHODS OF TREATMENT OF MUSCULAR DYSTROPHIESJanuary 2022September 2024Abandon3201NoNo
17627506METHOD FOR SELF-ASSEMBLY OF A PROTEIN ON A SUBSTRATE IN A THREE-DIMENSIONAL HONEYCOMB STRUCTUREJanuary 2022November 2025Abandon4601NoNo
17572792METHOD FOR PROMOTING WOUND HEALINGJanuary 2022January 2024Abandon2410NoNo
17571499USES OF ANTI-SIRPg ANTIBODIESJanuary 2022February 2025Allow3731NoNo
17647210TREATMENT OF HIDRADENITIS SUPPURATIVAJanuary 2022October 2023Abandon2110NoNo
17570010METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITISJanuary 2022September 2025Abandon4520NoYes
17549017LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAMEDecember 2021February 2024Allow2620YesNo
17539034ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTORNovember 2021September 2023Allow2110NoNo
17537020TOPICAL ERYTHROPOIETIN FORMULATIONS AND METHODS FOR IMPROVING WOUND HEALING WITH AND COSMETIC USE OF THE FORMULATIONSNovember 2021June 2025Allow4341NoYes
17534909CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENTNovember 2021June 2025Abandon4321NoNo
17612878ANTI-CD137L ANTIBODIES AND METHODS OF USING SAMENovember 2021July 2025Abandon4401NoNo
17600842DIAGNOSIS AND TREATMENT FOR CHRONIC INFLAMMATION AND VIRUS INFECTIONOctober 2021June 2025Allow4411NoNo
17486833METHODS OF TREATING MULTIPLE MYELOMA CANCERS EXPRESSING HIGH LEVELS OF EPO-RECEPTOR USING PSA-EPOSeptember 2021September 2024Abandon3621NoNo
17483967POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40LSeptember 2021August 2025Allow4731NoNo
17473459COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESISSeptember 2021November 2023Abandon2601NoNo
17410324PDGF RECEPTOR BETA BINDING POLYPEPTIDESAugust 2021December 2023Abandon2710NoNo
17383319COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPOJuly 2021September 2023Abandon2601NoNo
17379504LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAMEJuly 2021May 2024Abandon3420NoNo
17338869METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSISJune 2021June 2023Abandon2510NoNo
17293623ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONSMay 2021April 2025Abandon4701NoNo
17193057Sustained Response Predictors After Treatment with Anti-IL23 AntibodyMarch 2021January 2026Allow5850NoYes
17173214NBP158 AND USES THEREOFFebruary 2021June 2023Allow2810NoNo
17172856ANTI-ACVR1 ANTIBODIES AND USES THEREOFFebruary 2021November 2023Allow3311NoNo
17164438METHODS OF PRODUCING LONG ACTING CTP-MODIFIED POLYPEPTIDESFebruary 2021February 2025Abandon4821NoNo
17264470UNIVERSAL CHIMERIC RECEPTORSJanuary 2021September 2025Abandon5621NoNo
17145653Method for purifying PEGylated erythropoietinJanuary 2021August 2023Allow3110NoNo
17127766Variant Antibody That Binds Cd38December 2020December 2025Allow6020NoNo
17123465BISPECIFIC ANTI-CCL2 ANTIBODIESDecember 2020March 2023Allow2701NoNo
17103260TREATMENT OF HIDRADENITIS SUPPURATIVANovember 2020January 2024Abandon3720NoNo
17055646CH3 DOMAIN EPITOPE TAGSNovember 2020March 2025Abandon5211NoNo
17050894REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENT SCREENING METHOD, AND REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENTOctober 2020June 2024Abandon4401NoNo
17080268METHOD FOR TREATING PULMONARY FIBROSIS USING S100A3 PROTEINOctober 2020January 2024Allow3911YesNo
17072298Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyOctober 2020August 2024Abandon4621NoYes
17048202FUSION PROTEIN BINDING TO CD47 PROTEIN AND APPLICATION THEREOFOctober 2020August 2023Allow3421NoNo
17060989METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIASOctober 2020December 2022Abandon2610NoNo
17060362ANTI-CCL17 ANTIBODIESOctober 2020April 2022Allow1800NoNo
16982759METHODS AND COMPOSITIONS FOR ALLERGIC DISORDERSSeptember 2020August 2023Abandon3421NoNo
17002665USING COLIPASE INHIBITORS TO TREAT PANCREATITISAugust 2020May 2021Abandon910NoNo
16989505METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASEAugust 2020September 2024Abandon4940NoNo
16988554NEMOLIZUMAB IN THE TREATMENT OF ATOPIC DERMATITIS WITH MODERATE TO SEVERE EXCORIATIONAugust 2020June 2025Allow5861YesNo
16941272ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USESJuly 2020March 2022Allow1900NoNo
16947265Production of Glycoproteins Using ManganeseJuly 2020December 2022Abandon2920NoNo
16963311THERAPEUTIC AGENT FOR ASTHMA CONTAINING IL-6 INHIBITORJuly 2020December 2025Allow6070NoNo
16959252THERAPEUTICS OF PTD-SMAD7 FUSION PROTEINSJune 2020September 2022Abandon2701NoNo
16957462PROCESS FOR PROVIDING PEGYLATED PROTEIN COMPOSITIONJune 2020September 2024Allow5140NoNo
16957160PROCESS FOR PROVIDING PEGYLATED PROTEIN COMPOSITIONJune 2020August 2022Allow2510NoNo
16772100Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked DiseasesJune 2020August 2023Abandon3811NoNo
16894265Methods For Treating Inflammatory Disorders and Traumatic Brain Injury Using Stabilized Non-Hematopoietic EPO Short PeptidesJune 2020September 2022Allow2721YesNo
16892973ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOFJune 2020September 2023Allow4011NoNo
16891413METHOD FOR PROMOTING WOUND HEALINGJune 2020October 2021Allow1620YesYes
16884905DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATIONMay 2020January 2024Allow4341NoNo
16880831METHODS OF TREATMENT OF MUSCULAR DYSTROPHIESMay 2020May 2022Abandon2421YesNo
16764788ANTI-IL-17 ANTIBODY/TNFR ECD FUSION PROTEIN AND USE THEREOFMay 2020January 2023Allow3221NoNo
16875159METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN ENHANCED PATIENT POPULATION USING BENRALIZUMABMay 2020March 2024Abandon4620NoNo
16611089METHOD FOR EXTENDING HALF-LIFE OF PROTEINMay 2020November 2023Abandon4921NoNo
16865086LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAMEMay 2020March 2021Allow1010NoNo
16855896PHARMACEUTICAL FORMULATIONSApril 2020November 2021Abandon1910NoNo
16652815Novel Senolytic PeptidesApril 2020January 2023Abandon3421NoNo
16650632NOVEL CONJUGATES AND USES THEREOFMarch 2020February 2022Abandon2211NoNo
16797253ANTIBODIES TO HUMAN ERYTHROFERRONE AND USES THEREOFFebruary 2020July 2021Allow1620NoNo
16792728PDGF RECEPTOR BETA BINDING POLYPEPTIDESFebruary 2020May 2021Allow1511NoNo
16637093METHOD FOR TREATING CANCER USING CD14 ANTAGONISTSFebruary 2020November 2023Allow4531NoNo
16782669ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDESFebruary 2020March 2024Abandon4921NoNo
16742759ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOFJanuary 2020March 2022Allow2621NoNo
16628427FC-GAMMA RECEPTOR MUTANTSJanuary 2020January 2023Allow3621NoNo
16724491METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASEDecember 2019August 2022Allow3221YesNo
16722952CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENTDecember 2019February 2022Abandon2521NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEBERRY, REGINA M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
6
(75.0%)
Examiner Reversed
2
(25.0%)
Reversal Percentile
37.8%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
124
Allowed After Appeal Filing
31
(25.0%)
Not Allowed After Appeal Filing
93
(75.0%)
Filing Benefit Percentile
33.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DEBERRY, REGINA M - Prosecution Strategy Guide

Executive Summary

Examiner DEBERRY, REGINA M works in Art Unit 1647 and has examined 786 patent applications in our dataset. With an allowance rate of 44.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner DEBERRY, REGINA M's allowance rate of 44.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DEBERRY, REGINA M receive 2.39 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DEBERRY, REGINA M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +38.3% benefit to allowance rate for applications examined by DEBERRY, REGINA M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.6% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 83.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.4% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.